Emerging RNA editing biomarkers will foster drug development

Area of Science:

• Neuroscience
• Pharmacology
• Biotechnology

Background:

• Adverse drug reactions (ADRs) affecting the central nervous system are a significant reason for drug development failure.
• Current methods for predicting these ADRs, primarily rodent behavior analysis, have questionable predictive accuracy.
• There is a critical need for more reliable, human-derived models for early-stage ADR assessment.

Purpose of the Study:

• To introduce and validate novel RNA editing biomarkers for predicting central nervous system ADRs.
• To establish a human-derived in vitro system for objective, mechanism-related biomarker quantification.
• To enable cost-effective, high-throughput drug screening for risk mitigation.

Main Methods:

• Utilized next-generation sequencing (NGS) for quantifying RNA editing biomarkers.
• Focused on adenosine-to-inosine RNA editing, a physiological process regulating synaptic protein function.
• Developed and applied in vitro models using human-derived cells.

Main Results:

• Demonstrated the predictive capability of RNA editing biomarkers for treatment-related suicidal ideation and behavior.
• Showcased the potential of NGS-based quantification for robust and high-throughput screening.
• Validated the utility of human-derived in vitro models over traditional animal testing.

Conclusions:

• RNA editing biomarkers offer a promising, objective method for predicting CNS ADRs.
• NGS-based quantification provides a scalable solution for early drug safety assessment.
• This approach can significantly improve drug development pipelines by mitigating risks associated with neurotoxic ADRs.